Replimune said it has resubmitted data for RP1, its oncolytic therapy for melanoma, prompting the FDA to grant a second review with a new decision date set for April 10. The company’s resubmission included additional analyses and a completed trial dataset intended to address deficiencies raised in an earlier regulatory review. STAT and other outlets flagged the unexpected regulatory timeline and noted the resubmission follows a summer rejection that left the program’s path uncertain. Replimune said the supplemental package clarifies efficacy signals and safety considerations and asked the agency to reconsider its earlier concerns. The new review creates a defined regulatory catalyst for investors and clinicians tracking oncolytic therapies; approval would mark a notable regulatory victory for a smaller immuno‑oncology developer.